Cem Gabay

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi [Behçet's syndrome]
    C Gabay
    Cem Gabay, Service de Rhumatologie, HUG, 1211 Geneve
    Rev Med Suisse 4:728-30, 732-3. 2008
  2. ncbi Pre-interleukin-1alpha expression reduces cell growth and increases interleukin-6 production in SaOS-2 osteosarcoma cells: Differential inhibitory effect of interleukin-1 receptor antagonist (icIL-1Ra1)
    Gaby Palmer
    Division of Rheumatology, University Hospital, Geneva, Switzerland Department of Pathology and Immunology, University of Geneva School of Medicine, Geneva, Switzerland
    Cytokine 31:153-60. 2005
  3. ncbi Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration
    Katerina Chatzidionysiou
    Department of Rheumatology, Karolinska University Hospital, Stockholm, Sweden
    Ann Rheum Dis 71:374-7. 2012
  4. ncbi Magnetically retainable microparticles for drug delivery to the joint: efficacy studies in an antigen-induced arthritis model in mice
    Nicoleta Butoescu
    School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Quai Ernest Ansermet 30, 1211 Geneva, Switzerland
    Arthritis Res Ther 11:R72. 2009
  5. ncbi The role of leptin in innate and adaptive immune responses
    Eiva Bernotiene
    Department of Experimental Research, Institute of Experimental and Clinical Medicine, Vilnius University, Vilnius, Lithuania
    Arthritis Res Ther 8:217. 2006
  6. ncbi Diagnostic value of anti-cyclic citrullinated peptides and association with HLA-DRB1 shared epitope alleles in African rheumatoid arthritis patients
    Madeleine Singwe-Ngandeu
    Unit of Rheumatology, Department of Internal Medicine, School of Medicine, University of Yaounde, Yaounde, Cameroon
    Arthritis Res Ther 12:R36. 2010
  7. ncbi Production of interleukin-1 receptor antagonist by human articular chondrocytes
    Gaby Palmer
    Division of Rheumatology, University Hospital, Geneva, Switzerland
    Arthritis Res 4:226-31. 2002
  8. ncbi IL-1 pathways in inflammation and human diseases
    Cem Gabay
    Division of Rheumatology, University Hospitals of Geneva and Department of Pathology Immunology, University of Geneva School of Medicine, 26 Avenue Beau Sejour, 1211 Geneva 14, Switzerland
    Nat Rev Rheumatol 6:232-41. 2010
  9. ncbi IL-1 trap. Regeneron/Novartis
    Cem Gabay
    Division of Rheumatology, University Hospital of Geneva, 26 Avenue Beau Sejour, 1211 Geneva 14, Switzerland
    Curr Opin Investig Drugs 4:593-7. 2003
  10. ncbi Synovial tissues concentrate secreted APRIL
    Cem Gabay
    Division of Rheumatology, University Hospitals, 4 rue Gabrielle Perret Gentil, Geneva, CH 1211, Switzerland
    Arthritis Res Ther 11:R144. 2009

Detail Information

Publications96

  1. ncbi [Behçet's syndrome]
    C Gabay
    Cem Gabay, Service de Rhumatologie, HUG, 1211 Geneve
    Rev Med Suisse 4:728-30, 732-3. 2008
    ..The diagnosis of BS is primarily established on clinical grounds in the absence of specific biological marker. The treatment is tailored according to the severity of clinical manifestations. The prognosis is more severe in young men...
  2. ncbi Pre-interleukin-1alpha expression reduces cell growth and increases interleukin-6 production in SaOS-2 osteosarcoma cells: Differential inhibitory effect of interleukin-1 receptor antagonist (icIL-1Ra1)
    Gaby Palmer
    Division of Rheumatology, University Hospital, Geneva, Switzerland Department of Pathology and Immunology, University of Geneva School of Medicine, Geneva, Switzerland
    Cytokine 31:153-60. 2005
    ..Co-expression of icIL-1Ra1 did not antagonize this effect, indicating that intracellular effects of preIL-1alpha are not necessarily susceptible to inhibition by icIL-1Ra1...
  3. ncbi Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration
    Katerina Chatzidionysiou
    Department of Rheumatology, Karolinska University Hospital, Stockholm, Sweden
    Ann Rheum Dis 71:374-7. 2012
    ..To compare the effectiveness and safety of rituximab alone or in combination with either methotrexate or leflunomide...
  4. ncbi Magnetically retainable microparticles for drug delivery to the joint: efficacy studies in an antigen-induced arthritis model in mice
    Nicoleta Butoescu
    School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Quai Ernest Ansermet 30, 1211 Geneva, Switzerland
    Arthritis Res Ther 11:R72. 2009
    ..The purpose of this study was to investigate an innovative alternative consisting of corticosteroid encapsulation into magnetically retainable microparticles...
  5. ncbi The role of leptin in innate and adaptive immune responses
    Eiva Bernotiene
    Department of Experimental Research, Institute of Experimental and Clinical Medicine, Vilnius University, Vilnius, Lithuania
    Arthritis Res Ther 8:217. 2006
    ..Clinical studies have so far yielded inconsistent results, suggesting a rather complex role for leptin in immune-mediated inflammatory conditions in humans...
  6. ncbi Diagnostic value of anti-cyclic citrullinated peptides and association with HLA-DRB1 shared epitope alleles in African rheumatoid arthritis patients
    Madeleine Singwe-Ngandeu
    Unit of Rheumatology, Department of Internal Medicine, School of Medicine, University of Yaounde, Yaounde, Cameroon
    Arthritis Res Ther 12:R36. 2010
    ....
  7. ncbi Production of interleukin-1 receptor antagonist by human articular chondrocytes
    Gaby Palmer
    Division of Rheumatology, University Hospital, Geneva, Switzerland
    Arthritis Res 4:226-31. 2002
    ..In conclusion, human articular chondrocytes produce sIL-1Ra in response to IL-1beta and IL-6. The production of sIL-1Ra by chondrocytes may have a protective effect against articular inflammatory and catabolic responses...
  8. ncbi IL-1 pathways in inflammation and human diseases
    Cem Gabay
    Division of Rheumatology, University Hospitals of Geneva and Department of Pathology Immunology, University of Geneva School of Medicine, 26 Avenue Beau Sejour, 1211 Geneva 14, Switzerland
    Nat Rev Rheumatol 6:232-41. 2010
    ..Finally, preliminary results indicating that IL-1 targeting is efficacious in type 2 diabetes and smoldering myeloma have further broadened the spectrum of IL-1-driven diseases...
  9. ncbi IL-1 trap. Regeneron/Novartis
    Cem Gabay
    Division of Rheumatology, University Hospital of Geneva, 26 Avenue Beau Sejour, 1211 Geneva 14, Switzerland
    Curr Opin Investig Drugs 4:593-7. 2003
    ..Regeneron and Novartis are co-developing the interleukin (IL)-1 antagonist IL-1 trap for the potential treatment of rheumatoid arthritis. In July 2002, a phase II trial was initiated and results are expected mid-2003...
  10. ncbi Synovial tissues concentrate secreted APRIL
    Cem Gabay
    Division of Rheumatology, University Hospitals, 4 rue Gabrielle Perret Gentil, Geneva, CH 1211, Switzerland
    Arthritis Res Ther 11:R144. 2009
    ..However, little is known about APRIL expression in RA lesions, hampering our understanding of the way APRIL may modulate this autoimmune disease...
  11. ncbi Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study
    Cem Gabay
    University Hospitals of Geneva and University of Geneva, Geneva, Switzerland
    Arthritis Rheum 63:1486-96. 2011
    ..To identify the determinants of antibody responses to adjuvanted split influenza A (H1N1) vaccines in patients with inflammatory rheumatic diseases...
  12. ncbi The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases
    Cem Gabay
    Division of Rheumatology, University Hospitals of Geneva and Department of Pathology Immunology, University of Geneva Medical School, 1211 Geneva 14, Switzerland
    Arthritis Res Ther 11:230. 2009
    ..Targeting of some of these cytokines has already been tested in clinical trials with interesting results...
  13. ncbi Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center
    Cem Gabay
    University Hospitals of Geneva and University of Geneva School of Medicine, Geneva, Switzerland
    Arthritis Rheum 63:3383-91. 2011
    ..To evaluate the symptomatic effects of highly purified chondroitin 4 and chondroitin 6 sulfate (CS) therapy in patients with osteoarthritis (OA) of the hand...
  14. ncbi IL-1 inhibitors: novel agents in the treatment of rheumatoid arthritis
    C Gabay
    Division of Rheumatology, University Hospital of Geneva, 26 Avenue Beau Sejour, 1211 Geneva 14, Switzerland
    Expert Opin Investig Drugs 9:113-27. 2000
    ..Encouraging results also have been reported in both in vitro and in vivo experimental models of arthritis by using other strategies designed to block the effects of IL-1...
  15. ncbi Cytokine inhibitors in the treatment of rheumatoid arthritis
    Cem Gabay
    Division of Rheumatology, University Hospital of Geneva, 26 Avenue Beau Sejour, 1211 Geneva 14, Switzerland
    Expert Opin Biol Ther 2:135-49. 2002
    ..This review describes the results of clinical trials with TNF-alpha inhibitors and a specific IL-1 inhibitor (IL-1 receptor antagonist [IL-1Ra]). In addition, other therapeutic strategies are also discussed...
  16. ncbi Interleukin-6 and chronic inflammation
    Cem Gabay
    Division of Rheumatology, University Hospital of Geneva, Switzerland
    Arthritis Res Ther 8:S3. 2006
    ..Strategies targeting IL-6 and IL-6 signaling led to effective prevention and treatment of models of rheumatoid arthritis and other chronic inflammatory diseases...
  17. ncbi Production of IL-1 receptor antagonist by hepatocytes is regulated as an acute-phase protein in vivo
    C Gabay
    Division of Rheumatology, University Hospital of Geneva, Geneva, Switzerland
    Eur J Immunol 31:490-9. 2001
    ..In contrast, local production of IL-1Ra is independent of IL-6. Taken together, these results indicate that IL-1Ra is produced by the liver as an acute-phase protein in vivo...
  18. ncbi Expression and function of junctional adhesion molecule-C in human and experimental arthritis
    Gaby Palmer
    Division of Rheumatology, Department of Internal Medicine, University Hospital, 26 Avenue Beau Sejour, 1211 Geneva 14, Switzerland
    Arthritis Res Ther 9:R65. 2007
    ..Treatment of mice with an anti-JAM-C antibody significantly reduced the severity of AIA and delayed the onset of serum transfer-induced arthritis, suggesting a role for JAM-C in the pathogenesis of arthritis...
  19. ncbi Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis
    Gaby Palmer
    University Hospital of Geneva, and University of Geneva School of Medicine, Geneva, Switzerland
    Arthritis Rheum 60:738-49. 2009
    ..The aim of this study was to examine IL-33 production in human and mouse joints and to investigate the role of IL-33 and T1/ST2 in experimental arthritis...
  20. ncbi Distinct roles of hepatocyte- and myeloid cell-derived IL-1 receptor antagonist during endotoxemia and sterile inflammation in mice
    Celine Lamacchia
    Division of Rheumatology, University Hospitals of Geneva, Geneva, Switzerland
    J Immunol 185:2516-24. 2010
    ..Taken together, our observations define distinct roles for two major cellular sources of IL-1Ra in response to different types of systemic inflammatory stimuli in vivo...
  21. ncbi Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cell-specific interleukin-1 receptor antagonist
    Celine Lamacchia
    University of Geneva School of Medicine, Geneva, Switzerland
    Arthritis Rheum 62:452-62. 2010
    ..The purpose of this study was to investigate the role of IL-1Ra produced specifically by myeloid cells in the control of collagen-induced arthritis (CIA) by using myeloid cell-specific IL-1Ra-deficient mice (IL-1Ra(DeltaM))...
  22. ncbi CD14 is an acute-phase protein
    Sylvette Bas
    Division of Rheumatology, Department of Internal Medicine, University Hospital, Geneva, Switzerland
    J Immunol 172:4470-9. 2004
    ..Liver levels of CD14 mRNA increased in IL-6(+/+), but not in IL-6(-/-) mice. These results indicate that sCD14 can be considered as a type 2 APP...
  23. ncbi The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes
    David Magne
    Division of Rheumatology, Department of Internal Medicine, University Hospital and Department of Pathology and Immunology, University of Geneva School of Medicine, Geneva, Switzerland
    Arthritis Res Ther 8:R80. 2006
    ..It remains to be determined whether circulating IL-1F8 can contribute to joint inflammation in rheumatoid arthritis...
  24. ncbi The proinflammatory cytokine response to Chlamydia trachomatis elementary bodies in human macrophages is partly mediated by a lipoprotein, the macrophage infectivity potentiator, through TLR2/TLR1/TLR6 and CD14
    Sylvette Bas
    Division of Rheumatology, Department of Internal Medicine, University Hospital, and Department of Pathology and Immunology, Geneva Medical School, Switzerland
    J Immunol 180:1158-68. 2008
    ..Stimulating pathways appeared to involve TLR2/TLR1/TLR6 with the help of CD14 but not TLR4. These data support a role of Mip lipoprotein in pathogenesis of C. trachomatis-induced inflammatory responses...
  25. ncbi Articular inflammation is controlled by myeloid cell-derived interleukin 1 receptor antagonist during the acute phase of arthritis in mice
    Celine Lamacchia
    Division of Rheumatology, University Hospitals of Geneva, Switzerland
    Ann Rheum Dis 71:281-7. 2012
    ..To define the cell type (myeloid vs other cells) specific effect of interleukin 1 (IL-1) receptor antagonist (IL-1Ra) deficiency on the acute inflammatory phase of arthritis...
  26. ncbi The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes
    Gaby Palmer
    Division of Rheumatology, University Hospital, and Department of Pathology, University of Geneva School of Medicine, Geneva, Switzerland
    Arthritis Res Ther 6:R181-9. 2004
    ..The effect of A77 1726 may be partially mediated by inhibition of COX-2, but other mechanisms likely concur to stimulate IL-1Ra production...
  27. ncbi Delayed resolution of acute inflammation during zymosan-induced arthritis in leptin-deficient mice
    Eiva Bernotiene
    Division of Rheumatology, University Hospital and Department of Pathology, University of Geneva School of Medicine, Geneva, Switzerland
    Arthritis Res Ther 6:R256-63. 2004
    ..On the contrary, resolution of acute inflammation appears to be delayed in the absence of leptin or leptin signalling, suggesting that chronic leptin deficiency interferes with adequate control of the inflammatory response in ZIA...
  28. ncbi The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33
    Gaby Palmer
    Division of Rheumatology, University Hospital of Geneva, 26 Avenue Beau Sejour, 1211 Geneva 14, Switzerland
    Cytokine 42:358-64. 2008
    ..These observations identify AcP as a shared co-receptor within the IL-1 family that is essential for IL-33 signaling and suggest a novel role for sAcP in modulating the activity of IL-33...
  29. ncbi Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis
    Sophie Martin Du Pan
    Geneva University Hospital, Geneva, Switzerland
    Arthritis Rheum 61:560-8. 2009
    ..The aim of this study was to compare treatment retention rates and specific causes of anti-TNF discontinuation in a population-based RA cohort...
  30. ncbi Intracellular interleukin-1 receptor antagonist type 1 antagonizes the stimulatory effect of interleukin-1 alpha precursor on cell motility
    Faten Merhi-Soussi
    Division of Rheumatology, Department of Internal Medicine, University Hospital of Geneva, 26 avenue de Beau Séjour, 1211 Geneva 14, Switzerland
    Cytokine 32:163-70. 2005
    ..In conclusion, NIL-1alpha propiece increases ECV304 cell motility and icIL-1Ra1 exerts intracellular functions regulating this stimulatory effect...
  31. ncbi Adaptive immune response in JAM-C-deficient mice: normal initiation but reduced IgG memory
    Claudia Zimmerli
    Department of Pathology and Immunology, University of Geneva School of Medicine, Geneva, Switzerland
    J Immunol 182:4728-36. 2009
    ..Taken together, these data suggest that JAM-C deficiency affects the adaptive humoral immune response against pathogens, in addition to the innate immune system...
  32. ncbi Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients
    Axel Finckh
    Division of Rheumatology, Department of Internal Medicine, University Hospital of Geneva, 26, Avenue Beau Sejour, 1211 Geneva, Switzerland
    Joint Bone Spine 77:313-8. 2010
    ..Infliximab (IFX) can be immunogenic for humans and lead to the formation of antibodies against IFX (anti-IFX Ab), which could induce acquired IFX resistance...
  33. ncbi Interleukin-33 is biologically active independently of caspase-1 cleavage
    Dominique Talabot-Ayer
    Division of Rheumatology, University Hospital, and Department of Pathology and Immunology, University of Geneva School of Medicine, 1211 Geneva 4, Switzerland
    J Biol Chem 284:19420-6. 2009
    ..In addition, our results clearly show that caspase-1 cleavage is not required for pro-IL-33 secretion and bioactivity, highlighting major differences between IL-1beta and IL-33...
  34. ncbi Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis
    Nicolas Vuilleumier
    Geneva University Hospitals, Geneva, Switzerland
    Arthritis Rheum 62:2640-50. 2010
    ..To determine whether anti-apolipoprotein A-1 (anti-Apo A-1) IgG are associated with major cardiovascular events in patients with rheumatoid arthritis (RA)...
  35. ncbi IL-36R ligands are potent regulators of dendritic and T cells
    Solenne Vigne
    Division of Rheumatology and Department of Pathology Immunology, University of Geneva School of Medicine, Geneva, Switzerland
    Blood 118:5813-23. 2011
    ..Our data thus indicate a critical role of IL-36R ligands in the interface between innate and adaptive immunity, leading to the stimulation of T helper responses...
  36. ncbi B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents
    Axel Finckh
    University Hospital of Geneva, Geneva, Switzerland
    Arthritis Rheum 56:1417-23. 2007
    ..The aim of this study was to compare the effectiveness of RTX with that of an alternative anti-TNF agent in the management of patients with RA who had an inadequate response to anti-TNF therapy...
  37. ncbi The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study
    Diego Kyburz
    Department of Rheumatology, University Hospital of Zurich, Gloriastrasse 25, 8091 Zurich, Switzerland
    Rheumatology (Oxford) 50:1106-10. 2011
    ..To measure the long-term rate of radiographic progression in a cohort of patients treated early vs late with conventional DMARDs...
  38. ncbi Is IL-1 a good therapeutic target in the treatment of arthritis?
    Danielle Burger
    Clinical Immunology Unit, Division of Immunology and Allergy, Department of Internal Medicine, University Hospital, 24 Rue Micheli du Crest, CH 1211 Geneva 14, Switzerland
    Best Pract Res Clin Rheumatol 20:879-96. 2006
    ..Importantly, to be efficacious, anakinra required daily injections, suggesting that administered IL-1Ra displays very short-term effects. Better IL-1 antagonists are in the process of being developed...
  39. ncbi Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells
    David Moulin
    Division of Rheumatology, University Hospital, University of Geneva School of Medicine, 26 Avenue Beau Sejour, 1211, Geneva 14, Switzerland
    Cytokine 40:216-25. 2007
    ..These findings open new perspectives for the treatment of inflammatory diseases by targeting IL-33...
  40. ncbi The mouse interleukin (Il)33 gene is expressed in a cell type- and stimulus-dependent manner from two alternative promoters
    Dominique Talabot-Ayer
    Division of Rheumatology, University Hospital, and Department of Pathology and Immunology, University of Geneva School of Medicine, Geneva, Switzerland
    J Leukoc Biol 91:119-25. 2012
    ..Our data indicate that the Il33 gene is expressed from two alternative promoters in the mouse and that the relative expression of Il33a and Il33b transcripts is cell type- and stimulus-dependent...
  41. ncbi Indirect effects of leptin receptor deficiency on lymphocyte populations and immune response in db/db mice
    Gaby Palmer
    Department of Pathology and Immunology, University of Geneva School of Medicine, Switzerland
    J Immunol 177:2899-907. 2006
    ..In contrast, leptin receptor deficiency affects the immune system indirectly via changes in the systemic environment...
  42. ncbi Production of intracellular IL-1alpha, IL-1beta, and IL-1Ra isoforms by activated human dermal and synovial fibroblasts: phenotypic differences between human dermal and synovial fibroblasts
    Michel Maret
    Division of Rheumatology, Department of Internal Medicine, University Hospital and Department of Pathology and Immunology, University School of Medicine, Av Beau Séjour 26, 1211 Geneva 14, Switzerland
    Cytokine 25:193-203. 2004
    ..The presence of high amounts of icIL-1Ra1 and intracellular IL-1alpha in HDF suggests that these cytokines may carry out important function inside cells...
  43. ncbi Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study
    Stephane Genevay
    University Hospitals of Geneva, Geneva, Switzerland
    Arthritis Rheum 57:679-85. 2007
    ..The goal of the present study was to evaluate the tolerance to and effectiveness of anti-tumor necrosis factor (anti-TNF) agents in elderly patients (> or =65 years old) with RA (ERA) in comparison with younger patients (YRA)...
  44. ncbi Type I IL-1 receptor mediates IL-1 and intracellular IL-1 receptor antagonist effects in skin inflammation
    Gaby Palmer
    Division of Rheumatology, University Hospital, Geneva, Switzerland
    J Invest Dermatol 127:1938-46. 2007
    ..In conclusion, PMA-induced epidermal thickening and skin IL-1alpha expression were independent of IL-1 signaling, in contrast to dermal inflammation and systemic inflammatory response...
  45. ncbi Assessment of the efficacy of different statins in murine collagen-induced arthritis
    Gaby Palmer
    University Hospital and University of Geneva School of Medicine, Geneva, Switzerland
    Arthritis Rheum 50:4051-9. 2004
    ..It is still unclear whether statins will have benefit in the treatment of RA...
  46. ncbi Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice
    Faten Merhi-Soussi
    Division of Rheumatology, Department of Internal Medicine, University Hospital of Geneva, Switzerland
    Cardiovasc Res 66:583-93. 2005
    ..To examine the role of the balance between interleukin (IL)-1 and IL-1 receptor antagonist (IL-1Ra) in atherosclerosis and vascular inflammation...
  47. ncbi IL-1, IL-18, and IL-33 families of cytokines
    William P Arend
    Division of Rheumatology, University of Colorado Denver, School of Medicine, Denver, CO, USA
    Immunol Rev 223:20-38. 2008
    ..IL-18 provides an important link between the innate and adaptive immune responses. Newly described IL-33 binds to the orphan IL-1 family receptor T1/ST2 and stimulates T-helper 2 responses as well as mast cells...
  48. ncbi Serum lipoproteins attenuate macrophage activation and Toll-Like Receptor stimulation by bacterial lipoproteins
    Sylvette Bas
    Division of Rheumatology, Department of Internal Medicine, Geneva University Hospital, 1211 Geneva 14, Switzerland
    BMC Immunol 11:46. 2010
    ..Finally, TLR1/2 human embryonic kidney-293 (HEK-293) transfected cells were used to test the ability of the serum factors to inhibit Mip and OspA proinflammatory activity...
  49. ncbi Adalimumab in severe and acute sciatica: a multicenter, randomized, double-blind, placebo-controlled trial
    Stephane Genevay
    Hôpital Beau Séjour, University Hospitals of Geneva, Geneva, Switzerland
    Arthritis Rheum 62:2339-46. 2010
    ..Based on several experimental results and on a preliminary study, a trial was undertaken to assess the efficacy of adalimumab, a tumor necrosis factor alpha inhibitor, in patients with radicular pain due to lumbar disc herniation...
  50. ncbi Mice deficient in hepatocyte-specific IL-1Ra show delayed resolution of concanavalin A-induced hepatitis
    Celine Lamacchia
    Division of Rheumatology, University Hospital and Department of Pathology and Immunology, University of Geneva School of Medicine, Geneva, Switzerland
    Eur J Immunol 42:1294-303. 2012
    ..In conclusion, our results show that the local production of IL-1Ra by hepatocytes contributes to the resolution of hepatitis...
  51. ncbi Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure
    Nadia Announ
    Division of Rheumatology, Department of Internal Medicine, University Hospitals of Geneva and University of Geneva School of Medicine, Geneva, Switzerland
    Joint Bone Spine 76:424-6. 2009
    ..This observation suggests that anakinra is efficacious and safe for the prevention of crystal-induced arthritis in patients with severe renal failure...
  52. ncbi At the horizon of innovative therapy in rheumatology: new biologic agents
    Axel Finckh
    Division of Rheumatology, University Hospitals of Geneva and University of Geneva, Switzerland
    Curr Opin Rheumatol 20:269-75. 2008
    ..To review the rational and the results regarding the use of novel biologic agents in inflammatory rheumatic diseases...
  53. ncbi Mice transgenic for intracellular interleukin-1 receptor antagonist type 1 are protected from collagen-induced arthritis
    Gaby Palmer
    Division of Rheumatology, University Hospital, Geneva, Switzerland
    Eur J Immunol 33:434-40. 2003
    ..In conclusion, icIL-1Ra1, which is released into the extracellular space when produced in high amounts, has a similar anti-arthritic effect as sIL-1Ra...
  54. ncbi Absence of up-regulation for a proliferation-inducing ligand in Sjögren's sialadenitis lesions
    Tommaso Lombardi
    Laboratory of Oral Histopathology, Division of Stomatology, Faculty of Medicine, Department of Pathology Immunology, Geneva, Switzerland
    Rheumatology (Oxford) 50:1211-5. 2011
    ..To determine whether a proliferation-inducing ligand (APRIL) has a role in the survival of plasma cells infiltrating salivary glands from SS patients...
  55. ncbi Clinical evaluation of a cohort of patients with rheumatoid arthritis treated with anti-TNF-alpha in the community
    Marcia S Genta
    Division of Rheumatology, Department of Internal Medicine, University Hospital of Geneva, Switzerland
    Joint Bone Spine 73:51-6. 2006
    ..CONCLUSIONS: The responses of this community-based group of patients with severe, long-standing RA to TNF-alpha inhibitors revealed a reassuring similarity to those of patients enrolled in controlled clinical trials...
  56. ncbi [Radiculopathy due to lumbar disc herniation]
    Stephane Genevay
    Service de rhumatologie HUG, Hôpital Beau Séjour 26 Avenue Beau Séjour 1211 Genève 14
    Rev Med Suisse 5:577, 579-81. 2009
    ..This review focused on practical principles for the general practitioner...
  57. ncbi [Efficacy of tumor necrosis factor-alpha blockade for severe sciatica?]
    Stephane Genevay
    Service de rhumatologie HUG, Hôpital Beau Séjour, Geneve
    Rev Med Suisse Romande 124:543-5. 2004
    ..Two pilot studies realized on humans seem to confirm these experimental data. A multicenter randomised, double-blind, placebo controlled study is being planed in Switzerland...
  58. ncbi [Septic arthritis]
    C Medinger Sadowski
    Service de Rhumatologie, HUG, Clinique Beau Séjour, 1211 Geneve 14
    Rev Med Suisse 2:702-4, 707-8. 2006
    ..Age, chronic arthropathy, or arthroplasty are particularly associated with increased morbidity. Therapy consists in antibiotics, joint immobilisation (maximum 3 days) and medical drainage, in case of persisting joint effusion...
  59. ncbi Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study
    S Genevay
    Division of Rheumatology, University Hospital of Geneva, 26 Avenue Beau Sejour, 1211 Geneva 14, Switzerland
    Ann Rheum Dis 63:1120-3. 2004
    ..To explore the efficacy of a tumour necrosis factor alpha (TNFalpha) inhibitor (etanercept, Enbrel) in patients with severe sciatica...
  60. ncbi The effect of alcohol on radiographic progression in rheumatoid arthritis
    M J Nissen
    University Hospital of Geneva, Geneva, Switzerland
    Arthritis Rheum 62:1265-72. 2010
    ..This study was undertaken to compare the rates of radiographic damage progression in alcohol drinkers and nondrinkers in a large prospective cohort of patients with RA...
  61. ncbi [Rheumatological arthroscopy]
    T Duffy
    Service de Rhumatologie, Departement de Medecine Interne, HUG, 1211 Geneve 14
    Rev Med Suisse 1:701-2, 704. 2005
    ..The procedure can be carried out on an outpatient basis and is well tolerated by patients. In this article we will outline the practical concerns relating to rheumatological arthroscopy...
  62. ncbi Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
    A Finckh
    University Hospital of Geneva, Switzerland
    Ann Rheum Dis 69:387-93. 2010
    ..It remains unclear in which clinical settings these therapeutic strategies offer most benefit...
  63. ncbi Lower level of synovial fluid interferon-gamma in HLA-B27-positive than in HLA-B27-negative patients with Chlamydia trachomatis reactive arthritis
    S Bas
    Division of Rheumatology, Department of Internal Medicine, University Hospital, Geneva, Switzerland
    Rheumatology (Oxford) 42:461-7. 2003
    ....
  64. ncbi Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis
    S Bas
    Division of Rheumatology, Department of Internal Medicine, University Hospital, Geneva, Switzerland
    Rheumatology (Oxford) 42:677-80. 2003
    ....
  65. ncbi The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study
    A Finckh
    Division of Rheumatology, Department of Internal Medicine, University Hospital of Geneva, 26 Av Beau Sejour, 1211 Geneva 14 Switzerland
    Ann Rheum Dis 68:33-9. 2009
    ..In clinical routine, anti-TNF agents are commonly prescribed with other disease-modifying antirheumatic drugs (DMARDs) than MTX, however their effectiveness in combination with anti-TNF agents is not well established...
  66. ncbi Elevated levels of tumor necrosis factor-alpha in periradicular fat tissue in patients with radiculopathy from herniated disc
    S Genevay
    Division of Rheumatology, University Hospitals of Geneva, Geneva, Switzerland
    Spine (Phila Pa 1976) 33:2041-6. 2008
    ..Case-control study...
  67. ncbi Cigarette smoking and radiographic progression in rheumatoid arthritis
    A Finckh
    Division of Rheumatology, Department of Internal Medicine, University of Geneva, 26 Av Beau Sejour, 1211 Geneva 14, Switzerland
    Ann Rheum Dis 66:1066-71. 2007
    ..However, it remains unclear whether smoking influences RA disease progression and whether smokers have more radiographic damage progression than non-smokers over time...
  68. ncbi Discrimination of C57BL/6J Rj and 129S2/SvPasCrl inbred mouse strains by use of simple sequence length polymorphisms
    Celine Lamacchia
    Department of Pathology and Immunology, University of Geneva School of Mediicne, and Department of Internal Medicine, University Hospital, Switzerland
    J Am Assoc Lab Anim Sci 46:21-4. 2007
    ..This list of oligonucleotide pairs is useful for analyzing and backcrossing knockout or transgenic strains derived from 129S2/SvPasCrl or C57BL/6J Rj backgrounds...
  69. ncbi Molecular characterization and subcellular localization of macrophage infectivity potentiator, a Chlamydia trachomatis lipoprotein
    Laurence Neff
    Division of Rheumatology, Department of Internal Medicine, University Hospital, 1211 Geneva 14, Switzerland
    J Bacteriol 189:4739-48. 2007
    ....
  70. ncbi Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis
    Dominique Talabot-Ayer
    Division of Rheumatology, University Hospital, Geneva, Switzerland
    Joint Bone Spine 79:32-7. 2012
    ....
  71. ncbi Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapies
    Cedric Bandelier
    Clinique de Carouge, Réseau La Tour, Geneva, Switzerland
    Swiss Med Wkly 139:41-6. 2009
    ..Here we describe our clinical experience with MMF in several unusual indications...
  72. ncbi Interleukin-33 biology with potential insights into human diseases
    Gaby Palmer
    Division of Rheumatology, University Hospitals of Geneva and Department of Pathology Immunology, University of Geneva School of Medicine, 26 Avenue Beau Sejour, 1211 Geneva 14, Switzerland
    Nat Rev Rheumatol 7:321-9. 2011
    ..However, IL-33 also appears to exert important functions in host defense against pathogens and to display cardioprotective properties, which might have implications for the clinical use of IL-33 blockade...
  73. ncbi Autoimmunity and inflammation are independent of class II transactivator type PIV-dependent class II major histocompatibility complex expression in peripheral tissues during collagen-induced arthritis
    Jean Marc Waldburger
    University Medical Center and University of Geneva, Geneva, Switzerland
    Arthritis Rheum 63:3354-63. 2011
    ....
  74. ncbi Increased production of intracellular interleukin-1 receptor antagonist type I in the synovium of mice with collagen-induced arthritis: a possible role in the resolution of arthritis
    C Gabay
    Division of Rheumatology, University Hospital of Geneva, Switzerland
    Arthritis Rheum 44:451-62. 2001
    ..These results suggest that icIL-1Ra1 may play a role in the resolution of murine CIA...
  75. ncbi A systematic review of infliximab in the treatment of early rheumatoid arthritis
    Sophie Martin Du Pan
    Division of Rheumatology, Department of Internal Medicine, University of Geneva
    Ther Clin Risk Manag 3:905-11. 2007
    ..The aim of this systematic review of the literature was to appraise the efficacy, safety, and cost-effectiveness of early therapy with IFX...
  76. ncbi Images in clinical medicine. Milwaukee shoulder
    Marcia S Genta
    Geneva University Hospital, 1211 Geneva 14, Switzerland
    N Engl J Med 354:e2. 2006
  77. ncbi Systemic rheumatoid vasculitis: a review
    Marcia S Genta
    Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland
    Semin Arthritis Rheum 36:88-98. 2006
    ..To review the most recent information on the incidence, clinical course, pathology, pathogenesis, diagnosis, and treatment of rheumatoid vasculitis (RV), including the still scanty data on the use of biologics...
  78. ncbi Interferon beta stimulates interleukin 1 receptor antagonist production in human articular chondrocytes and synovial fibroblasts
    G Palmer
    Division of Rheumatology, University Hospital, and Department of Pathology, University of Geneva School of Medicine, Geneva, Switzerland
    Ann Rheum Dis 63:43-9. 2004
    ..CONCLUSION: IFNbeta increases IL1Ra production in joint cells, which may be beneficial in cartilage damaging diseases such as RA or osteoarthritis...
  79. ncbi A role for leptin in rheumatic diseases?
    G Palmer
    Division of Rheumatology, University Hospital of Geneva, Geneva, Switzerland
    Ann Rheum Dis 62:913-5. 2003
  80. ncbi [The differential diagnosis of tenosynovitis]
    Laure Brulhart
    Service de Rhumatologie, HUG, 1211 Geneve 14
    Rev Med Suisse 7:587-8, 590, 592-3. 2011
    ..Diabetes is a risk factor for most of them and is related to poor prognosis. Musculoskeletal ultrasound is useful for diagnosis and to guide procedure as fluid aspiration or steroid injection...
  81. ncbi Leptin directly induces the secretion of interleukin 1 receptor antagonist in human monocytes
    C Gabay
    Department of Internal Medicine, Division of Rheumatology, University Hospital Geneva, CH-1211 Geneva, Switzerland
    J Clin Endocrinol Metab 86:783-91. 2001
    ..These findings suggest that leptin may have immunomodulatory functions in vivo...
  82. ncbi Leptin signaling deficiency impairs humoral and cellular immune responses and attenuates experimental arthritis
    Nathalie Busso
    Laboratory of Rheumatology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Immunol 168:875-82. 2002
    ..In conclusion, leptin contributes to the mechanisms of joint inflammation in Ag-induced arthritis by regulating both humoral and cell-mediated immune responses...
  83. ncbi The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation
    Claire Jacques
    UMR 7079 CNRS, Physiology and Physiopathology Laboratory, University Paris 6, Paris, 75252 Cedex 5, France
    Vitam Horm 74:371-403. 2006
    ..Most importantly, these findings have been confirmed in clinical trials in patients with rheumatic diseases. Additional strategies aimed to block the effect of IL-1 are tested in clinical trials...
  84. ncbi Specific role of interleukin-1 in hepatic neutrophil recruitment after ischemia/reperfusion
    Atsushi Kato
    Department of Surgery, University of Cincinnati College of Medicine, Ohio 45267, USA
    Am J Pathol 161:1797-803. 2002
    ..These data suggest that IL-1 functions to augment neutrophil accumulation, but does not play an essential role in this response...
  85. ncbi The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study
    Axel Finckh
    Robert B Brigham Atthritis and Musculoskeletal Diseases Clinical Research Center, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Arthritis Rheum 54:54-9. 2006
    ..The 3 strategies were infliximab with concomitant disease-modifying antirheumatic drugs (DMARDs), etanercept with concomitant DMARDs, and etanercept alone...
  86. ncbi [Review of the protective effects of tumor necrosis factor inhibitors in rheumatoid arthritis]
    Axel Finckh
    Arthritis and Musculoskeletal Clinical Research Center, Department of Medicine, Brigham and Women s Hospital, Boston, USA
    Rev Med Suisse Romande 124:547-50. 2004
    ..We also touch on the notion of a therapeutic window of opportunity early in the course of RA, as early initiation of aggressive treatment seems to provide a sustained benefit on radiographic progression...
  87. ncbi Anti-inflammatory effects of hepatocyte growth factor: induction of interleukin-1 receptor antagonist
    Clemens Molnar
    Clinical Division of General Internal Medicine, Clinical Department of Internal Medicine, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria
    Eur Cytokine Netw 15:303-11. 2004
    ....
  88. ncbi Leukocyte migration to rheumatoid joints: Enzymes take over
    Gaby Palmer
    Arthritis Rheum 54:2707-10. 2006
  89. ncbi Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis
    Paul Emery
    Academic Unit of Musculoskeletal Disease, Leeds University, Chapel Town Road, Leeds, LS7 4S, UK
    Rheumatol Int 27:793-806. 2007
    ....
  90. ncbi [Rheumatic diseases and infections]
    Alexander So
    Rev Med Suisse 2:699. 2006
  91. ncbi IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin?
    Christoph A Meier
    Division of Endocrinology and Diabetes, Department of Internal Medicine, University Hospital Geneva
    J Clin Endocrinol Metab 87:1184-8. 2002
    ....
  92. ncbi Total hip prosthetic joint infection due to Veillonella species
    Anne Zaninetti-Schaerer
    Joint Bone Spine 71:161-3. 2004
  93. ncbi Cytokines in the rheumatic diseases
    William P Arend
    Division of Rheumatology, University of Colorado Health Sciences Center B1115, 4200 East Ninth Avenue, Denver, CO 80262, USA
    Rheum Dis Clin North Am 30:41-67, v-vi. 2004
    ..This article summarizes the role of cytokines in rheumatic diseases by focusing on each disease and the involved pathways of pathophysiology...
  94. ncbi Leptin activates the promoter of the interleukin-1 receptor antagonist through p42/44 mitogen-activated protein kinase and a composite nuclear factor kappa B/PU.1 binding site
    Magali G Dreyer
    Endocrine Unit, Division of Endocrinology, Diabetes and Nutrition, University Hospital Geneva, 24, rue Micheli-du-Crest, CH-1211 Geneva 14, Switzerland
    Biochem J 370:591-9. 2003
    ..1 composite element of the IL-1Ra promoter...